Preliminary prospective cohort data from the Yale COVID-19 Cardiovascular Registry showed that at least 40% of patients hospitalised with verified COVID-19 had a high cardiovascular (CV) risk at baseline, including a high prevalence of diabetes and hypertension. Patients with CV risk in the Yale registry cohort had high mortality rates and CV complications; about 1 in 5 patients died, 2 in 5 experienced a CV event, and 1 in 5 required mechanical ventilation .
Dr Manan Pareek (Yale University School of Medicine, USA) presented the data, which was intended to supplement the sparse body of evidence suggesting that patients with a high CV risk or disease burden tend to be more vulnerable during SARS-CoV-2 infection. The aim of the analysis was to determine the prevalence of CV risk factors, established CV disease, and associated medications. Additionally, they sought to identify risk factors for incident CV events and mortality. Using the Yale New Haven Hospital COVID-19 Cardiovascular Registry, Dr Pareek and colleagues performed a prospective cohort study including 1,200 hospitalised patients positive for COVID-19 (median age 68 years; 54% male). Dr Pareek presented the analysis of the first 495 patients.
The primary endpoint was in-hospital death from any cause. Secondary endpoints were CV outcomes, such as major adverse CV event (MACE), and non-CV outcomes, such as intensive care admission, mechanical ventilation, and renal replacement therapy. Within the first 495 patients, more than 40% presented with CV risk factors, among which diabetes, hypertension, and hyperlipidaemia were the most common. In addition, 46% of the cohort had a history of any CV disease, the most prevalent being coronary artery disease (CAD), heart failure, and atrial fibrillation; accordingly, medication use by this cohort was frequent, including antihypertensives, aspirin, and statins.
In-hospital CV events included atrial fibrillation (19%), myocardial infarction (17%), and acute decompensated heart failure (14%). Non-CV related events were intensive care admission (35%), mechanical ventilation (21%), and dialysis (4%). Furthermore, 18% of patients died in hospital, and 39% experienced a MACE after admission. Applying logistic regression to determine potential predictors of MACE, independent variables were male gender, history of atrial fibrillation, use of a diuretic, oxygen therapy at admission, low albumin, and high troponin T levels. Similarly, in-hospital mortality was characterised by independent variables of age, a history of ventricular tachycardia, use of P2Y12 inhibitors, lower platelet count, higher aspartate aminotransferase, lower albumin, and high troponin T levels.
Limitations of the study included the observational nature of the study as well as the limited event rate and short follow-up. Because all participants were hospital patients, the population was generally older with more comorbidities than the non-hospitalised COVID-19 patients.
- Pareek M, et al. YNHHS-COVID-19 – Cardiac Complications Registry. COVID and Cardiovascular Disease session, ESC Congress 2020, 30 Aug.
« COVID-19 treatments and the importance of randomised trials Next Article
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan »
Table of Contents: ESC 2020
Letter from the Editor
ESC 2020 Highlights Podcast
2020 ESC Clinical Practice Guidelines
2020 Atrial Fibrillation Guidelines
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
2020 Adult Congenital Heart Disease Guidelines
Hot Line Presentations
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy
Reduced cardiovascular outcomes with early rhythm control
Trimetazidine after successful PCI not associated with fewer cardiac events
POPular TAVI: Aspirin-only antiplatelet strategy?
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Antihypertensives also reduce CV risk in people with normal blood pressure
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Drug initiation strategy not associated with increased use of oral anticoagulants
Restrictive blood transfusion non-inferior and cost-effective strategy
Increased mortality with colchicine in patients with ACS
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins
Antisense ANGPTL3 lowers triglycerides
Reduced progression of coronary atherosclerosis with icosapent ethyl
Digoxin improves symptoms in stable patients with permanent AF
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
COVID and Cardiovascular Disease
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials
2020 Atrial Fibrillation Guidelines